You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated Dynamic Lists for Efficient Electronic Health Record Management

    SBC: Clinacuity, Inc            Topic: NCI

    DESCRIPTION (provided by APPLICANT): Medical errors are recognized as the cause of numerous deaths, and even if some are difficult to avoid, many are preventable. Computerized physician order-entry systems with decision support have been proposed to reducethis risk of medication errors, but these systems rely on structured and coded information in the electronic health record (EHR). Unfortunately, ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Aptamer-based Glycomics Tools

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Protein glycosylation plays very important roles in biological processes. However, detecting and differentiating such modifications rapidly is not a trivial issue. Therefore, developing novel tools that allow for the rapid detection of glycosylation patterns is of tremendous importance to the field of glycomics. In this application, we propose to develop a nove ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury

    SBC: Allinaire Therapeutics, LLC            Topic: NHLBI

    Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation

    SBC: Courier Therapeutics Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT Systemic administration of high dose ILhas been used since thes as an FDA approved immunotherapy for metastatic cancerDespite the fact that up toof patients treated with high dose ILachieve a durablelong term responsethis therapy is rarely used today due to significant life threatening complicationsSuch complications occur due to ILactivation of vascular endotheliumresulti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid development of a Zika-specific diagnostic test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract Miami has emerged as the US epicenter of the now global Zika virusZIKVepidemicThe consequences of infection remain to be fully elucidatedbut the probable link between ZIKV infection and fetal developmental complications raises enormous concern as to the potential impact of ZIKVCurrent emergency use authorizationEUAcommercial assays detect ZIKV RNAthe presence of ZIKV speci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Overcoming anti-PD-1 resistance by systemic delivery of an oncolytic adenovirus that targets TGF-beta

    SBC: Multivir Inc.            Topic: 102

    Project Summary The overall goal of this proposal is to test a novel systemic Adenoviral therapy that targets transforming growth factorTGFand reverses anti PDresistance to treat advanced breast and lung cancersThis STTR grant application illustrates the synergistic relationship between DrPrem Sethinventor of a novel TGFdecoyand MultiVir Inca leader in clinical development of gene based therapeuti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIDDK

    ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government